Search results
Results From The WOW.Com Content Network
The first-line treatment is generally given to patients as an initial antiretroviral therapy and is the cheapest of the stages of treatments. [1] The first-line antiretroviral drug treatment as recommended by the World Health Organization (WHO) involves TDF (tenofovir), 3TC (lamivudine) or FTC (emtricitabine), and EFV (efavirenz) or dolutegravir (DTG).
The World Health Organization (WHO) issued consultative recommendations regarding nutrient requirements in HIV/AIDS. [6] A generally healthy diet was promoted. For HIV-infected adults, the WHO recommended micronutrient intake comes from a good diet at RDA levels; higher intake of vitamin A, zinc, and iron can produce adverse effects in HIV positive adults, and these were not recommended unless ...
00:38. Lenacapavir’s current list price for use as HIV treatment is $3,450 per month. Gilead has not yet indicated whether it will set a different price for the drug’s use as PrEP. A company ...
Management of HIV/AIDS. The management of HIV/AIDS normally includes the use of multiple antiretroviral drugs as a strategy to control HIV infection. [1] There are several classes of antiretroviral agents that act on different stages of the HIV life-cycle. The use of multiple drugs that act on different viral targets is known as highly active ...
Treatment as prevention. Treatment as prevention (TasP) is a concept in public health that promotes treatment as a way to prevent and reduce the likelihood of HIV illness, death and transmission from an infected individual to others. Expanding access to earlier HIV diagnosis and treatment as a means to address the global epidemic by preventing ...
The World Health Organization (WHO) recognizes that harm reduction is central to the prevention of HIV amongst people who inject drugs (PWID) and their sexual and drug using partners. [15] Social strategies do not require any drug or object to be effective, but rather require persons to change their behaviors to gain protection from HIV.
Pre-exposure prophylaxis for HIV prevention, commonly known as PrEP, is the use of antiviral drugs as a strategy for the prevention of HIV/AIDS by people that do not yet have HIV/AIDS. [1] PrEP is one of a number of HIV prevention strategies for people who are HIV negative but who have a higher risk of acquiring HIV, including sexually active ...
As of 2019, it is listed by the World Health Organization (WHO) as the first-line treatment for adults with HIV/AIDS, with tenofovir/lamivudine/efavirenz as an alternative. [2] It may be used in people with both HIV and tuberculosis, however if the person is on rifampicin a larger dose of dolutegravir is needed. [2]